查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018066

神經診斷市場：按技術、應用和最終用戶分類－2026-2032年全球市場預測

Neurodiagnostics Market by Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經診斷市場價值將達到 87 億美元，到 2026 年將成長到 95 億美元，到 2032 年將達到 168.6 億美元，複合年成長率為 9.90%。

主要市場統計數據
基準年 2025 87億美元
預計年份：2026年 95億美元
預測年份 2032 168.6億美元
複合年成長率 (%) 9.90%

對不斷發展的神經診斷生態系統進行簡要概述，為決策者概述臨床需求、技術轉折點和策略重點。

神經診斷目前正處於轉折點，感測技術、數據分析和醫療服務模式的進步正在融合，重塑神經系統疾病的檢測、表徵和監測方式。臨床醫師越來越需要能夠提供更高空間和時間解析度，同時又能相容於門診和居家照護路徑的診斷工具。同時，醫療設備開發商和臨床檢查室也被寄予厚望，需要展現互通性和臨床效用，並創造高效的工作流程，以縮短診斷時間，改善病患體驗。

這是一個重大的結構和技術轉折點，它將重塑神經系統疾病的檢測、監測和管理方式，無論在何種醫療環境下。

神經診斷領域正經歷一場變革，其驅動力包括技術的成熟、醫療服務模式的轉變以及對疾病生物學機制的新認知。非侵入性影像和電生理技術的進步提高了診斷的敏感性和特異性，而侵入性監測技術由於小型化和生物相容性的提高，變得更加精準，也減輕了患者的負擔。同時，雲端平台的普及也推動了這些技術的進步，使得更高級的訊號處理、基於機器學習的模式識別以及連續的患者監測和遠端專家評估成為可能。

貿易政策和關稅趨勢的變化如何影響神經診斷整個價值鏈的供應鏈韌性、採購選擇和定價策略？

預期中的關稅措施及相關貿易政策可能對神經診斷技術的供應鏈、零件採購和定價策略產生重大影響。進口關稅的變化及相關合規要求往往會增加醫療設備製造商的採購複雜性，這些製造商通常從全球供應商採購專用感測器、積體電路和成像組件。因此，製造商正在探索替代籌資策略、近岸外包方案以及垂直整合，以降低關稅波動帶來的風險並維持其利潤率結構。

深入理解高解析度分割技術，將技術進步、臨床應用和最終用戶需求與策略研究和商業化選擇連結起來。

市場區隔洞察為產品設計、臨床檢驗和商業化策略的協調提供了切實可行的觀點。將技術分為侵入性和非侵入性方法時，侵入性方法著重於深層電極監測和皮質腦電圖。這些方法通常用於外科手術和嚴格控制的醫院環境，需要嚴格的無菌操作、生物相容性以及與神經外科工作流程的整合。非侵入性方法著重於傳統的電生理學和各種成像技術。這些方法需要在解析度、可近性和患者舒適度之間取得平衡，以滿足門診和長期監測應用的需求。

從區域比較的觀點，將主要全球市場的監管細微差別、醫療保健服務管道和實施前提條件連結起來。

區域趨勢對臨床准入途徑、監管預期和夥伴關係可能性有顯著影響。在美洲，臨床網路的特點是擁有完善的醫院系統、不斷擴展的門診醫療基礎設施，並高度重視以報銷主導的價值證明。這種環境有利於開發能夠與複雜的電子健康記錄系統整合，並能顯著提高工作流程效率和改善患者預後的解決方案。該地區的監管機構高度重視臨床檢驗和上市後證據，直接影響臨床試驗設計和真實世界證據（RWE）策略。

這是策略競爭策略和夥伴關係關係在醫療設備創新、分析和綜合臨床服務領域確立市場領導地位的典型例子。

神經診斷領域的競爭動態是由醫療設備創新、軟體驅動的分析、臨床夥伴關係和服務模式的相互作用所塑造的。主要參與者包括醫療設備檢驗的合約研究組織 (CRO) 以及提供遠端監測和診斷支援的臨床服務供應商。

為旨在加速臨床導入、降低供應風險和發展永續收入來源的公司提供可操作的策略重點和營運策略。

行業領導企業應優先進行一系列協調一致的努力，將技術進步轉化為永續的臨床和商業性成果。首先，他們必須投資於實證策略，使臨床檢驗與目標終端使用者的具體需求相契合，確保研究能夠反映門診、診斷中心、醫院和居家照護等場所的真實工作流程。這種方法透過展示設備在真實環境中的實際益處，降低了推廣應用的門檻。

採用嚴謹的混合方法研究方法，結合與臨床醫師的對話、文獻整合和情境分析，以檢驗策略意義並確定實際限制。

本分析所依據的研究採用了一種混合方法，結合了質性研究和嚴謹的文獻綜述。主要資訊來源包括神經內科和神經外科的臨床醫生、醫院和診斷中心的採購經理、醫療設備工程師以及衛生經濟學專家。透過這些訪談，我們了解到了工作流程整合、臨床檢驗終點和採購決策標準等方面的實際考量。

將策略意義和營運重點有效結合起來，將技術能力與整個臨床環境中切實可行的實施路徑連結起來。

總而言之，神經診斷領域正從孤立的、以設備為中心的解決方案轉向整合感測、分析和服務交付的整合平台，以滿足分散式醫療保健的需求。有創和非侵入性技術的進步正在拓展臨床應用的可能性，但成功實用化需要仔細考慮最終用戶的工作流程、證據生成、監管合規性以及穩健的供應鏈設計。能夠根據特定臨床應用的細微需求客製化產品開發，並建立加速證據收集和與支付方合作的夥伴關係的相關利益者，將最有能力將創新轉化為持久的臨床影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：神經診斷市場：依技術分類

  • 侵入性
    • 深電極監測
    • 皮層電位記錄
  • 非侵入性
    • 電生理學
    • 診斷影像

第9章：神經診斷市場：依應用領域分類

  • 阿茲海默症
    • 路易氏體失智症
    • 血管性失智症
  • 腦腫瘤
  • 癲癇
    • 局部性癲癇發作
    • 整體癲癇
  • 多發性硬化症
  • 中風
    • 出血性中風
    • 缺血性中風
  • 創傷

第10章 神經診斷市場：依最終使用者分類

  • 門診部
    • 神經科診所
    • 門診復健中心
  • 診斷中心
    • 醫院營運的診斷中心
    • 獨立診斷中心
  • 居家照護
  • 醫院
    • 綜合醫院
    • 專科診所
  • 研究機構

第11章：神經診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：神經診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：神經診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國神經診斷市場

第15章：中國神經診斷市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Brain Monitoring, Inc.
  • BioSerenity
  • Brainscope Co. Inc.
  • Cadwell Laboratories, Inc.
  • Canon Medical Systems Corporation
  • Compumedics Limited
  • Electrical Geodesics, Inc.
  • F. Hoffmann-La Roche Ltd
  • FUJIFILM Holdings Corporation
  • GE HealthCare Corporation
  • Koninklijke Philips NV
  • Lifelines Neuro Company, LLC
  • Medtronic plc
  • Natus Medical Incorporated
  • NeuroMetrix, Inc.
  • Neurosigma, Inc.
  • NeuroSky, Inc.
  • Neurosoft
  • Nicolet Neurodiagnostic Products, Inc.
  • Nihon Kohden Corporation
  • Persyst Development Corporation
  • Rhythmlink International, LLC
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-030226489D71

The Neurodiagnostics Market was valued at USD 8.70 billion in 2025 and is projected to grow to USD 9.50 billion in 2026, with a CAGR of 9.90%, reaching USD 16.86 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.70 billion
Estimated Year [2026] USD 9.50 billion
Forecast Year [2032] USD 16.86 billion
CAGR (%) 9.90%

A concise orientation to the evolving neurodiagnostics ecosystem that frames clinical needs, technology inflection points, and strategic priorities for decision-makers

Neurodiagnostics sits at an inflection point where advances in sensing technologies, data analytics, and care delivery models are converging to reshape how neurological disorders are detected, characterized, and monitored. Clinicians increasingly demand diagnostic tools that deliver higher spatial and temporal resolution while fitting into outpatient and home-based care pathways. At the same time, device developers and clinical labs face rising expectations to demonstrate interoperability, clinical utility, and streamlined workflows that reduce time-to-diagnosis and improve patient experience.

This executive summary distills the latest shifts across technology, clinical applications, end-user environments, regulatory landscapes, and commercial strategies to help leaders make informed decisions. It synthesizes qualitative insights from key opinion leaders and operational stakeholders alongside rigorous evidence from peer-reviewed clinical studies and regulatory documents. The intent is to present an integrated perspective that balances clinical imperatives with practical implementation constraints, thereby enabling stakeholders to prioritize investment, refinement, and partnership opportunities that drive measurable clinical impact.

Throughout the analysis, emphasis is placed on actionable implications for product development, clinical adoption, and strategic alliances. By framing challenges and opportunities in concrete programmatic terms, this summary enables executive teams, clinical innovators, and commercialization leads to chart pragmatic roadmaps for translating technological promise into routine clinical practice.

Key structural and technological inflection points reshaping how neurological conditions are detected, monitored, and managed across care settings

The neurodiagnostics landscape is undergoing transformative shifts driven by technological maturation, changing care delivery models, and new evidence around disease biology. Advances in noninvasive imaging and electrophysiology are improving diagnostic sensitivity and specificity, while invasive monitoring techniques are becoming more targeted and less disruptive through miniaturization and improved biocompatible designs. These technological strides are accompanied by more sophisticated signal processing, machine learning-enabled pattern recognition, and cloud-based platforms that facilitate longitudinal patient monitoring and remote specialist review.

Concurrently, care delivery is decentralizing. Hospital-centric workflows are being complemented by ambulatory clinics, diagnostic centers, and home care models that prioritize patient convenience and continuous monitoring. This shift requires devices and platforms to be robust, user-friendly, and compatible with telehealth infrastructures. Regulatory pathways are also adapting to a landscape where software and hardware co-evolve, placing greater emphasis on clinical validation, real-world evidence, and post-market surveillance.

Finally, commercial dynamics are changing as stakeholders seek integrated solutions that combine hardware, analytics, and services. Partnerships across medtech, software, and clinical networks are accelerating, and reimbursement conversations increasingly hinge on demonstrated improvements in diagnostic accuracy, care efficiency, and downstream clinical outcomes. These combined forces are reshaping priorities for R&D investments and go-to-market strategies across the sector.

How evolving trade policy and tariff dynamics are likely to affect supply chain resilience, procurement choices, and pricing strategies across the neurodiagnostics value chain

Anticipated tariff measures and related trade policy actions can materially influence supply chains, component sourcing, and pricing strategies for neurodiagnostic technologies. Changes in import duties and related compliance requirements tend to increase procurement complexity for device manufacturers that source specialized sensors, integrated circuits, and imaging components from a global supplier base. As a result, manufacturers are examining alternative sourcing strategies, nearshoring options, and vertical integration to mitigate exposure to tariff volatility and to preserve margin structures.

These dynamics ripple downstream to healthcare providers and payers. Procurement cycles for hospitals and diagnostic centers may extend as purchasing teams reassess total cost of ownership and the comparative economics of domestic versus imported systems. Meanwhile, smaller ambulatory clinics and home care providers are likely to be more sensitive to price shifts and may delay purchasing decisions or prioritize modular platforms that can be upgraded incrementally.

From a strategic perspective, companies that proactively model tariff scenarios and incorporate supply chain flexibility into product design will be better positioned to maintain competitive pricing and minimize disruptions. Investments in component standardization, supplier diversification, and localized assembly can reduce lead-time risk and support more predictable service delivery. Ultimately, resilient supply chain design coupled with transparent communication to clinical customers will be essential for maintaining adoption momentum amid trade policy uncertainty.

High-resolution segmentation insights that connect technology pathways, clinical applications, and end-user requirements to strategic research and commercialization choices

Insight into market segmentation provides a practical lens to align product design, clinical validation, and commercialization strategies. When technology is parsed into invasive and noninvasive approaches, invasive modalities emphasize depth electrode monitoring and electrocorticography, which are typically deployed in surgical or highly controlled inpatient settings and require rigorous sterility, biocompatibility, and integration with neurosurgical workflows. Noninvasive pathways emphasize conventional electrophysiology and a range of imaging modalities that must balance resolution, accessibility, and patient comfort to support outpatient and longitudinal monitoring applications.

Application-based segmentation highlights where clinical evidence and unmet needs intersect. Diagnostic and monitoring priorities span Alzheimer's disease, where differential diagnosis includes Lewy body and vascular dementia subtypes; focal and generalized epilepsy; brain tumors; multiple sclerosis; stroke, with hemorrhagic and ischemic subtypes; and trauma. Each indication imposes distinct requirements on diagnostic performance, temporal resolution, and integration with therapeutic interventions, shaping how technologies are validated and positioned to clinicians.

End-user segmentation across ambulatory clinics, diagnostic centers, home care, hospitals, and research institutes reveals divergent adoption drivers. Ambulatory clinics, including neurology clinics and outpatient rehabilitation centers, emphasize ease of use and workflow efficiency. Diagnostic centers, whether hospital-owned or independent, balance throughput and reimbursement considerations. Hospitals, including general hospitals and specialty clinics, prioritize diagnostic accuracy and interoperability with electronic medical records, while research institutes focus on experimental flexibility and advanced analytics. Understanding these segmentation nuances is essential for tailoring evidence generation, regulatory strategies, and commercial engagement models.

A comparative regional perspective that links regulatory nuance, care delivery pathways, and adoption prerequisites across major global markets

Regional dynamics materially influence clinical adoption pathways, regulatory expectations, and partnership potential. In the Americas, clinical networks are characterized by established hospital systems, a growing ambulatory care infrastructure, and a strong emphasis on reimbursement-driven value demonstration. This environment encourages solutions that can integrate with complex electronic health record systems and deliver measurable improvements in workflow efficiency and patient outcomes. Regulatory agencies in the region place substantial weight on clinical validation and post-market evidence, shaping clinical trial designs and real-world evidence strategies.

In Europe, the Middle East & Africa, heterogeneous healthcare systems create diverse pathways to adoption. Some markets prioritize national health technology assessment and centralized procurement, while others rely on private providers and direct hospital acquisitions. This diversity requires adaptable commercialization strategies that account for varying reimbursement frameworks, clinical practice patterns, and infrastructure constraints. Meanwhile, the Asia-Pacific region presents a spectrum from highly centralized, large-scale hospital networks to rapidly growing outpatient and home care markets. In several countries, strong investments in digital health and telemedicine create opportunities for remote monitoring and AI-enabled diagnostics, but market entry often requires local partnerships and sensitivity to regulatory nuances.

Across all regions, strategic market entry benefits from a phased approach that prioritizes clinical demonstration in representative care settings, cultivates local clinical champions, and aligns product configurations with regional procurement and care delivery norms.

Strategic competitive moves and partnership archetypes that define market leadership in device innovation, analytics, and integrated clinical services

Competitive dynamics in neurodiagnostics are shaped by the interplay between device innovation, software-enabled analytics, clinical partnerships, and service models. Key players span established medical device manufacturers that bring scale, regulatory experience, and distribution networks, as well as specialized technology firms focused on high-resolution sensors, advanced signal processing, and machine learning. Other influential participants include software vendors offering integrated analytics platforms, contract research organizations that facilitate clinical validation, and clinical service providers enabling remote monitoring and interpretation.

Leading organizations are differentiating through strategic investments in clinical evidence generation, interoperability, and multi-stakeholder partnerships. Product roadmaps emphasize modular platforms that accommodate both hardware upgrades and software algorithm updates, supporting long-term clinical utility and amortized procurement. Additionally, companies that develop clear value narratives tied to improved diagnostic accuracy, reduced time-to-treatment, or lower downstream costs tend to accelerate payer and provider engagement.

Collaborative models are also emerging as critical competitive levers. Joint development agreements with academic centers, data partnerships to enrich algorithm training sets, and service-based business models that bundle diagnostics with interpretation and care coordination services are becoming more prevalent. These strategic orientations reflect an industry-wide shift from point-solution selling toward integrated offerings designed to deliver measurable clinical and economic value.

Actionable strategic priorities and operational levers for companies seeking to accelerate clinical adoption, mitigate supply risks, and unlock recurring revenue streams

Industry leaders should prioritize a set of coordinated actions to convert technical advances into durable clinical and commercial outcomes. First, invest in evidence-generation strategies that align clinical validation with the precise needs of target end users, ensuring that studies mirror real-world workflows in ambulatory clinics, diagnostic centers, hospitals, and home care environments. This approach reduces barriers to adoption by demonstrating practical benefits in the settings where devices will be used.

Second, design platforms for modularity and interoperability so that hardware improvements and algorithmic enhancements can be deployed incrementally without requiring full system replacement. This lowers procurement barriers and supports long-term customer relationships. Third, cultivate diversified supply chains and localized assembly options to insulate operations from tariff fluctuations and to shorten lead times for critical components. Fourth, build business models that combine device sales with analytic services, training, and remote interpretation to create recurring revenue streams and deeper clinical integration.

Finally, prioritize partnerships with clinical leaders, payer advocates, and technology integrators to accelerate acceptance and reimbursement. These collaborations should be structured to generate real-world evidence and to create clear pathways for scaling adoption across regions with distinct regulatory and reimbursement environments.

A rigorous mixed-methods research approach combining clinician engagement, literature synthesis, and scenario analysis to validate strategic implications and identify practical constraints

The research underpinning this analysis employed a mixed-methods approach combining primary qualitative engagement and rigorous secondary review. Primary inputs included structured interviews with clinicians across neurology and neurosurgery, procurement leads from hospitals and diagnostic centers, device engineers, and health economics specialists. These conversations informed practical considerations around workflow integration, clinical validation endpoints, and procurement decision criteria.

Secondary research drew on peer-reviewed clinical literature, regulatory filings, device labeling information, and real-world implementation case studies to triangulate primary findings and validate technical assertions. Data synthesis followed systematic protocols to ensure consistency in theme extraction, and multiple rounds of internal validation were conducted to reconcile divergent inputs. Analytical methods included thematic coding of qualitative interviews, cross-case comparison across care settings, and scenario analysis to test the resilience of strategic recommendations under alternative supply chain and regulatory conditions.

Limitations of the methodology include variability in clinical practice patterns across regions and the evolving nature of software-driven diagnostics, which can change rapidly as algorithms are retrained on new datasets. To mitigate these limitations, recommendations are framed as adaptive strategies that emphasize iterative validation and staged implementation rather than one-time investments.

A cogent synthesis of strategic implications and operational priorities that bridge technological capability with pragmatic adoption pathways across clinical environments

In summary, neurodiagnostics is transitioning from isolated, device-centric solutions toward integrated platforms that combine sensing, analytics, and service delivery to meet the needs of decentralized care. Technology improvements in both invasive and noninvasive modalities are expanding clinical possibilities, but successful translation requires attention to end-user workflows, evidence generation, regulatory alignment, and resilient supply chain design. Stakeholders who align product development with the nuanced requirements of specific clinical applications, and who craft partnerships that accelerate evidence collection and payer engagement, will be best positioned to translate innovation into sustained clinical impact.

Actionable priorities include designing modular, interoperable systems; investing in representative clinical validation across ambulatory, inpatient, and home-based settings; and implementing supply chain strategies that moderate exposure to tariff and trade policy volatility. By combining these operational steps with value-based commercial narratives and collaborative research partnerships, organizations can effectively bridge the gap between technological capability and routine clinical adoption. The end result should be diagnostics that improve timeliness and accuracy of neurological assessment while fitting seamlessly into contemporary care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurodiagnostics Market, by Technology

  • 8.1. Invasive
    • 8.1.1. Depth Electrode Monitoring
    • 8.1.2. Electrocorticography
  • 8.2. Noninvasive
    • 8.2.1. Electrophysiology
    • 8.2.2. Imaging Modalities

9. Neurodiagnostics Market, by Application

  • 9.1. Alzheimer's Disease
    • 9.1.1. Lewy Body Dementia
    • 9.1.2. Vascular Dementia
  • 9.2. Brain Tumor
  • 9.3. Epilepsy
    • 9.3.1. Focal Epilepsy
    • 9.3.2. Generalized Epilepsy
  • 9.4. Multiple Sclerosis
  • 9.5. Stroke
    • 9.5.1. Hemorrhagic Stroke
    • 9.5.2. Ischemic Stroke
  • 9.6. Trauma

10. Neurodiagnostics Market, by End User

  • 10.1. Ambulatory Clinics
    • 10.1.1. Neurology Clinics
    • 10.1.2. Outpatient Rehabilitation Centers
  • 10.2. Diagnostic Centers
    • 10.2.1. Hospital Owned Diagnostic Centers
    • 10.2.2. Independent Diagnostic Centers
  • 10.3. Home Care
  • 10.4. Hospitals
    • 10.4.1. General Hospitals
    • 10.4.2. Specialty Clinics
  • 10.5. Research Institutes

11. Neurodiagnostics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Neurodiagnostics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Neurodiagnostics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Neurodiagnostics Market

15. China Neurodiagnostics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Advanced Brain Monitoring, Inc.
  • 16.6. BioSerenity
  • 16.7. Brainscope Co. Inc.
  • 16.8. Cadwell Laboratories, Inc.
  • 16.9. Canon Medical Systems Corporation
  • 16.10. Compumedics Limited
  • 16.11. Electrical Geodesics, Inc.
  • 16.12. F. Hoffmann-La Roche Ltd
  • 16.13. FUJIFILM Holdings Corporation
  • 16.14. GE HealthCare Corporation
  • 16.15. Koninklijke Philips N.V.
  • 16.16. Lifelines Neuro Company, LLC
  • 16.17. Medtronic plc
  • 16.18. Natus Medical Incorporated
  • 16.19. NeuroMetrix, Inc.
  • 16.20. Neurosigma, Inc.
  • 16.21. NeuroSky, Inc.
  • 16.22. Neurosoft
  • 16.23. Nicolet Neurodiagnostic Products, Inc.
  • 16.24. Nihon Kohden Corporation
  • 16.25. Persyst Development Corporation
  • 16.26. Rhythmlink International, LLC
  • 16.27. Siemens Healthineers AG
  • 16.28. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEURODIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEURODIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEURODIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA NEURODIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEURODIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DEPTH ELECTRODE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DEPTH ELECTRODE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DEPTH ELECTRODE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ELECTROCORTICOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ELECTROCORTICOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ELECTROCORTICOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ELECTROPHYSIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ELECTROPHYSIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ELECTROPHYSIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY LEWY BODY DEMENTIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY LEWY BODY DEMENTIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY LEWY BODY DEMENTIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY VASCULAR DEMENTIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY VASCULAR DEMENTIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY BRAIN TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY BRAIN TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY BRAIN TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY FOCAL EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY FOCAL EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY FOCAL EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY GENERALIZED EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY GENERALIZED EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY GENERALIZED EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY TRAUMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY TRAUMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY TRAUMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY OUTPATIENT REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY OUTPATIENT REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY OUTPATIENT REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOSPITAL OWNED DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOSPITAL OWNED DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOSPITAL OWNED DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INDEPENDENT DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INDEPENDENT DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INDEPENDENT DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 214. GCC NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 216. GCC NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GCC NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 249. G7 NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 250. G7 NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 254. G7 NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. G7 NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 264. NATO NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 266. NATO NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. NATO NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA NEURODIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA NEURODIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA NEURODIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA NEURODIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA NEURODIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA NEURODIAGNOSTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA NEURODIAGNOSTICS MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA NEURODIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)